Latest News and Press Releases

Optimi Health, ATMA Sign Letter of Intent To Advance Phase II Clinical Trial Group and Individual Administration Protocol For Major Depressive Disorder

Optimi Health Receives Certificate of Analysis For GMP MDMA 40mg and 60mg MDMA Capsules.

Optimi Health provides corporate update.

Optimi Health announces innovative research and development partnership with the Kwantlen Polytechnic University Applied Genomics Centre.

Optimi announces completion of three batches of its MDMA API manufactured from raw materials under the Company’s Precursor Licence.

Optimi receives Certificate Of Analysis for GMP Natural Psilocybin Extract. Company has also completed the in-house encapsulation of 5mg & 10mg psilocybin.

Supply agreement marks Optimi’s first international shipment of research-grade active pharmaceutical ingredient (API) MDMA to Israel

VANCOUVER, British Columbia, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a Health Canada licensed drug researcher and...

Optimi Health Congratulates Lykos Therapeutics on FDA Priority Review of New Drug Application And Releases MDMA Production Video

Optimi Announces Non-Brokered Private Placement